Current directions in tau research: Highlights from Tau 2020

Claire Sexton; Heather Snyder; Dirk Beher; Adam L. Boxer; Pat Brannelly; Jean Pierre Brion; Luc Buée; Angela M. Cacace; Gaël Chételat; Martin Citron; Sarah L. DeVos; Kristophe Diaz; Howard H. Feldman; Bess Frost; Alison M. Goate; Michael Gold; Bradley Hyman; Keith Johnson; Celeste M. Karch; Diana R. Kerwin; Walter J. Koroshetz; Irene Litvan; Huw R. Morris; Catherine J. Mummery; James Mutamba; Marc C. Patterson; Yakeel T. Quiroz; Gil D. Rabinovici; Amy Rommel; Melanie B. Shulman; Leticia M. Toledo-Sherman; Stacie Weninger; Kristin R. Wildsmith; Susan L. Worley; Maria C. Carrillo

doi:10.1002/alz.12452

Current directions in tau research: Highlights from Tau 2020

Claire Sexton, Heather Snyder, Dirk Beher, Adam L. Boxer, Pat Brannelly, Jean Pierre Brion, Luc Buée, Angela M. Cacace, Gaël Chételat, Martin Citron, Sarah L. DeVos, Kristophe Diaz, Howard H. Feldman, Bess Frost, Alison M. Goate, Michael Gold, Bradley Hyman, Keith Johnson, Celeste M. Karch, Diana R. KerwinWalter J. Koroshetz, Irene Litvan, Huw R. Morris, Catherine J. Mummery, James Mutamba, Marc C. Patterson, Yakeel T. Quiroz, Gil D. Rabinovici, Amy Rommel, Melanie B. Shulman, Leticia M. Toledo-Sherman, Stacie Weninger, Kristin R. Wildsmith, Susan L. Worley, Maria C. Carrillo

Research output: Contribution to journal › Review article › peer-review

45 Scopus citations

Abstract

Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

Original language	English
Pages (from-to)	988-1007
Number of pages	20
Journal	Alzheimer's and Dementia
Volume	18
Issue number	5
DOIs	https://doi.org/10.1002/alz.12452
State	Published - May 2022

Keywords

Alzheimer's
biomarkers
neurodegeneration
tau
therapeutics

Access to Document

10.1002/alz.12452

Cite this

Sexton, C., Snyder, H., Beher, D., Boxer, A. L., Brannelly, P., Brion, J. P., Buée, L., Cacace, A. M., Chételat, G., Citron, M., DeVos, S. L., Diaz, K., Feldman, H. H., Frost, B., Goate, A. M., Gold, M., Hyman, B., Johnson, K., Karch, C. M., ... Carrillo, M. C. (2022). Current directions in tau research: Highlights from Tau 2020. Alzheimer's and Dementia, 18(5), 988-1007. https://doi.org/10.1002/alz.12452

@article{9f92429fb1f04534b4b6da5d5ea04d85,

title = "Current directions in tau research: Highlights from Tau 2020",

abstract = "Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.",

keywords = "Alzheimer's, biomarkers, neurodegeneration, tau, therapeutics",

author = "Claire Sexton and Heather Snyder and Dirk Beher and Boxer, {Adam L.} and Pat Brannelly and Brion, {Jean Pierre} and Luc Bu{\'e}e and Cacace, {Angela M.} and Ga{\"e}l Ch{\'e}telat and Martin Citron and DeVos, {Sarah L.} and Kristophe Diaz and Feldman, {Howard H.} and Bess Frost and Goate, {Alison M.} and Michael Gold and Bradley Hyman and Keith Johnson and Karch, {Celeste M.} and Kerwin, {Diana R.} and Koroshetz, {Walter J.} and Irene Litvan and Morris, {Huw R.} and Mummery, {Catherine J.} and James Mutamba and Patterson, {Marc C.} and Quiroz, {Yakeel T.} and Rabinovici, {Gil D.} and Amy Rommel and Shulman, {Melanie B.} and Toledo-Sherman, {Leticia M.} and Stacie Weninger and Wildsmith, {Kristin R.} and Worley, {Susan L.} and Carrillo, {Maria C.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2022",

month = may,

doi = "10.1002/alz.12452",

language = "English",

volume = "18",

pages = "988--1007",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "5",

}

Sexton, C, Snyder, H, Beher, D, Boxer, AL, Brannelly, P, Brion, JP, Buée, L, Cacace, AM, Chételat, G, Citron, M, DeVos, SL, Diaz, K, Feldman, HH, Frost, B, Goate, AM, Gold, M, Hyman, B, Johnson, K, Karch, CM, Kerwin, DR, Koroshetz, WJ, Litvan, I, Morris, HR, Mummery, CJ, Mutamba, J, Patterson, MC, Quiroz, YT, Rabinovici, GD, Rommel, A, Shulman, MB, Toledo-Sherman, LM, Weninger, S, Wildsmith, KR, Worley, SL & Carrillo, MC 2022, 'Current directions in tau research: Highlights from Tau 2020', Alzheimer's and Dementia, vol. 18, no. 5, pp. 988-1007. https://doi.org/10.1002/alz.12452

TY - JOUR

T1 - Current directions in tau research

T2 - Highlights from Tau 2020

AU - Sexton, Claire

AU - Snyder, Heather

AU - Beher, Dirk

AU - Boxer, Adam L.

AU - Brannelly, Pat

AU - Brion, Jean Pierre

AU - Buée, Luc

AU - Cacace, Angela M.

AU - Chételat, Gaël

AU - Citron, Martin

AU - DeVos, Sarah L.

AU - Diaz, Kristophe

AU - Feldman, Howard H.

AU - Frost, Bess

AU - Goate, Alison M.

AU - Gold, Michael

AU - Hyman, Bradley

AU - Johnson, Keith

AU - Karch, Celeste M.

AU - Kerwin, Diana R.

AU - Koroshetz, Walter J.

AU - Litvan, Irene

AU - Morris, Huw R.

AU - Mummery, Catherine J.

AU - Mutamba, James

AU - Patterson, Marc C.

AU - Quiroz, Yakeel T.

AU - Rabinovici, Gil D.

AU - Rommel, Amy

AU - Shulman, Melanie B.

AU - Toledo-Sherman, Leticia M.

AU - Weninger, Stacie

AU - Wildsmith, Kristin R.

AU - Worley, Susan L.

AU - Carrillo, Maria C.

PY - 2022/5

Y1 - 2022/5

N2 - Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

AB - Studies supporting a strong association between tau deposition and neuronal loss, neurodegeneration, and cognitive decline have heightened the allure of tau and tau-related mechanisms as therapeutic targets. In February 2020, leading tau experts from around the world convened for the first-ever Tau2020 Global Conference in Washington, DC, co-organized and cosponsored by the Rainwater Charitable Foundation, the Alzheimer's Association, and CurePSP. Representing academia, industry, government, and the philanthropic sector, presenters and attendees discussed recent advances and current directions in tau research. The meeting provided a unique opportunity to move tau research forward by fostering global partnerships among academia, industry, and other stakeholders and by providing support for new drug discovery programs, groundbreaking research, and emerging tau researchers. The meeting also provided an opportunity for experts to present critical research-advancing tools and insights that are now rapidly accelerating the pace of tau research.

KW - Alzheimer's

KW - biomarkers

KW - neurodegeneration

KW - tau

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85115826817&partnerID=8YFLogxK

U2 - 10.1002/alz.12452

DO - 10.1002/alz.12452

M3 - Review article

C2 - 34581500

AN - SCOPUS:85115826817

SN - 1552-5260

VL - 18

SP - 988

EP - 1007

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 5

ER -

Current directions in tau research: Highlights from Tau 2020

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this